摘要
Abstract
Objective:To compare the efficacy of Ranibizumab and compacept in the treatment of senile wet macular degenera-tion.Methods:48 cases of patients with senile wet macular degenerationwere selected as research subjects.The patients were divided into control group (n=24) and study group (n=24) according to admission order.The control group was treated with Ranibizumab treatment,the study group was treated with Compacept treatment,the efficacy of the two medications was compared.Results:The vision of the patients in the study group was (0.29+0.10) at the first month after the operation,the control group was (0.38+0.08),the difference was statistically significant(P<0.05).In the study group,the retinal thickness of macular fovea was(355.2+52.6)μm at the first month,and the control group was (345.5+53.3)μm,the difference was statistically significant (P<0.05).The recurrence rate of CNV in the study group was lower than those in the control group,and the effective rate was higher than the control group(P<0.05).The number of injections in the study group was(4.79+1.26) times,the number of injections in the control group was(4.01+1.01) times,the difference was statistically significant (P<0.05).Conclusions:The effect of compacept in the treatment of senile wet macular degeneration is better than rezumab,and the effect is equal to the latter.However,compacept can reduce the incidence of CNV infiltration in patients with fewer injection times,and has a high clinical value.关键词
雷珠单抗/康柏西普/老年湿性黄斑病变/视网膜厚度Key words
Rezumab/Compacept/Senile wet macular degeneration/Retinal thickness分类
医药卫生
